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Abstract: Several evidences suggest that a small population of cells known as cancer stem cells (CSCs) or tumor initiating stem-
like cells within a tumor is capable of tumor initiation, maintenance and propagation. Recent publications have supported the
existence of CSCs in pancreatic tumors. The pancreatic stem/progenitor cells, which express self-renewalmarkers, are identified
to be present in the peribiliary gland. Based on the CSC hypothesis, mutations can lead to the transformation of stem/progenitor
cells or differentiated cells intoCSCs. ThepancreaticCSCsexpress awide array ofmarkers suchasCD44,CD24, ESA,CD133, c-
MET, CXCR4, PD2/Paf1 andALDH1. TheCSCs are isolated basedon surfacemarkers or by othermethods such asALDEFLOUR
assay or Hoechst 33342 dye exclusion assay. The isolated cells are further characterized by in vitro and in vivo tumorigenic
assays. The most important characteristics of CSCs are its ability to self-renew and impart drug resistance towards chemo-
therapy.Moreover, these distinct cells display alteration of signaling pathways pertaining toCSCs such asNotch,Wnt andShh to
maintain the self-renewal process. Failure of cancer treatment could be attributed to the therapy resistance exhibited by the
CSCs. Metastasis and drug resistance in pancreatic cancer is associated with epithelial to mesenchymal transition (EMT).
Furthermore, mucins, the high molecular weight proteins are found to be associated with pancreatic CSCs and EMT.
Understanding the underlying molecular pathways that aid in the metastatic and drug resistant nature of these distinct cells
will aid in targeting these cells. Overall, this review focuses on the various aspects of pancreatic adult/stem progenitors, CSC
hypothesis, its markers, pathways, niche, EMT and novel therapeutic drugs used for the elimination of pancreatic CSCs.




CXCR4 - Cysteine-x-cysteine chemokine receptor 4
DCLK1 - Doublecortin-like kinase 1
SOX2 - Sex-determining region Y (SRY)-Box2
PDAC - Pancreatic ductal adenocarcinoma
CSC - Cancer stem cell
SP - Side population
NSP - Non side population
EMT - Epithelial to mesechymal transition
INTRODUCTION
Pancreatic cancer is one of the most lethal cancers among
all solid malignancies. According to the National cancer
institute, it has been estimated that approximately 46,420
new cases and 39,590 deaths would be reported in the year
2014 [1]. The incidence rates have been increasing for
pancreatic cancer over the past several years. Currently,
pancreatic cancer has been listed as the fourth leading
cause of death due to cancer and by 2020 it is predicted
to be ranked as the second leading cause of cancer related
deaths [2]. On the positive side, the survival rate has
increased from 3% to 6.7% in the past 35 years. There
are several risk factors associated with this disease. Pri-
marily, cigarette smoking has been the largest known
risk factor for pancreatic cancer development [3, 4].
Other well-known risk factors such as obesity, pan-
creatitis, diabetes and other forms of tobacco usage are
associated with the development of pancreatic cancer. In
addition, those individuals who have a strong family
history of pancreatic cancer aremore prone to an increased
risk of developing pancreatic cancer [5]. Approximately,
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5–10% of pancreatic ductal adenocarcinoma (PDAC)
cases are hereditary with nearly 80% penetrance [6, 7].
Pancreatic cancer is not just a single entity caused by a
single mutation; it has various precursors which arise due
to multiple mutations.
The three precursors for pancreatic cancer are the
highly occurring precursor; such as the pancreatic intrae-
pithelial neoplasia (PanINs), and less commonly occurring
precursors such as; intraductal papillary mucinous neo-
plasm (IPMN) and mucinous cystic neoplasm (MCN) [8].
Histologically, normal pancreas undergoes a series of
morphological changes giving rise to low grade PanINs
which eventually gives rise to high grade PanINs [9].
These PanIN lesions eventually develop into infiltrative
adenocarcinoma [10]. Many genetic alterations were
defined in pancreatic cancer such as earlier events includ-
ing K-ras point mutation, EGFR overexpression and gene
amplification and HER2/neu overexpression and later
events such as inactivation of p16, p53, DPC4 and BRCA.
Considering the genetic alterations, currently there are
several animal models developed to study the progression
of pancreatic cancer [9]. Animal models are developed to
recapitulate the genetic alterations of the human pancre-
atic cancer and also they serve as a tool to understand the
mechanisms underlying the disease.
In the recent past various animal models have been
developed using the Cre-Lox technology such as Pdx1-
Cre; LSL-KrasG12D, Ptf1/p48-Cre; LSL-KrasG12D and
LSL-KrasG12D/C/Mist1Cre-ER/ [11–13]. Eventually, ani-
mal models harboring additional modifications such as
inactivation/mutation of p16, p19, p53, transforming
growth factor (TGFb) and smad4 were developed
[14–16]. These in vivo models help in understanding the
progression of pancreatic cancer from lower to higher
grade lesions which slowly develops to invasive carcino-
ma and finally to metastasis. Although several aspects of
PDAC have been studied so far, the evidences for the
emergence of pancreatic cancer from cancer stem cells
have been quite limited but intriguing as well.
Cancer stem cells (CSCs) or tumor initiating stem-like
cells (TICs) are a small subset of cancer cells which are
capable of self-renewal and resist various chemotherapeu-
tic drugs [17]. This sub-population behaves like stem cells
by undergoing either asymmetric or symmetric cell divi-
sion thereby maintaining its population within the cancer.
CSCs have been identified in various cancers including
brain, breast, ovarian, prostate, pancreatic and colon
[18–25]. Simeone et al. [20], demonstrated the presence
of CSCs in pancreatic cancer for the first time. Pancreatic
CSCs were characterized by CD44C CD24C and ESAC
markers. Eventually, several pieces of evidence have
cropped up to prove the existence of pancreatic CSCs
[26–28]. These pieces of evidence emphasize the impor-
tance of identifying pancreatic cancer stem cells. Simul-
taneously, targeting these CSCs in pancreatic cancer has
become another challenging area of interest. In this review
article, we will summarize the earlier findings of pancre-
atic cancer stem cells, the potential techniques used to
enrich and characterize pancreatic CSCs, pancreatic CSC
niche, the various signaling pathways involved in the
maintenance of pancreatic CSCs, drug resistance and
EMT, mucins in pancreatic CSCs and the current strate-
gies used to target pancreatic CSCs.
INDENTIFICATION OF PANCREATIC CANCER
STEM CELLS
By the year 2006, many studies reported the existence of
CSCs in various cancers [18, 22, 29]. After several years of
CSC discovery, the first evidence for the existence of
pancreatic CSCs was reported by two groups in the year
2007 [20, 30]. Li et al. [20], demonstrated that the CD44C
CD24CESAC cells isolated from human PDAC could self-
renew, had differentiation potential, and had enhanced
Shh expression. Subcutaneous injection of 500 cells (pos-
itive for CD44, CD24 and ESA) in mice could generate
tumors (7/12 mice) whereas implantation of pancreatic
cancer cells negative for these markers could not. Equally
significant, a second study showed the presence of pan-
creatic CSCs having the ability to metastasize. Notably,
the CD133CCXCR4C CSC subpopulation isolated from
pancreatic tumors displayed metastatic activity [30].
Emerging evidence demonstrates that the ZEB1-micro-
RNA200 feedback loop is essential to promote the migra-
tory CSCs in pancreatic cancer [31].
Later in 2011, c-Metwas identified as an importantCSC
marker in pancreatic cancer [28]. Strikingly, the c-Met
expressingCSCs (c-Methigh) had the ability to give rise to a
larger tumor as opposed to no tumor formation in the c-
Met negative cells. A c-met inhibitor such as XL184 could
reduce the CSC population [28]. Subsequently, Van den
Broeck et al. [26], used a different method to study the
pancreatic CSCs [26]. They have isolated side population
(SP) and non-side population (NSP) from PDAC surgical
resection specimens using the Hoechst 33342 dye based
FACS analysis. Two important genes such as ABCB1, a
multidrug resistance transporter as well as CXCR4, a
chemokine receptor were found to be upregulated in the
SP fraction as opposed to the NSP fraction. They also
demonstrated that these two genes have been associated
with the worst patient survival. It has been suggested that
this subpopulation of cancer cells such as the CSCs should
be the prime target for therapy.
A recent study demonstrated that SOX2, a transcription
factor which plays a role in the embryonic development
has been found to cause de-differentiation thereby impart-
ing stemcell-like characteristics to pancreatic cancer cells.
SOX2 is absent in the normal acinar or ductal compart-
ment. However, its expression has been observed in 19.3%
of human pancreatic tumors. The study suggested that
SOX2 positive cancer cells could serve as an essential
therapeutic target; as its expression has significantly
increased in the ESAC/CD44C CSC population, and is
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also found to regulate genes controlling EMT and G1/S
transition thereby contributing to dedifferentiation and
stemness [32]. The latest work by Bailey et al. [27],
demonstrated the existence of a distinct population of
pancreatic cancer initiating cells in KCPdx, KCiMist1 and
KPCPdx mice expressing DCLK1 which is a microtubule
regulator. They have also demonstrated that pancreatic
CSCs could be identified at very early stages such as in
PanIN 1 (Pancreatic intraepithelial neoplasia-1) in KPC
mice. Altogether, these evidences clearly validate the
presence of CSC subpopulation in pancreatic cancer.
ORIGIN OF PANCREATIC CANCER STEM CELL
HYPOTHESIS
During the embryonic developmental stage, pancreas
develops as dorsal and ventral evaginations from the
foregut endoderm in the 5th week of gestation [33]. Cells
from the dorsal and ventral buds slowly undergo lineage
commitment to either of the two compartments such as the
endocrine and the exocrine compartments. The endocrine
compartment comprises the islets while the exocrine
compartment is organized into acinar, ductal and centroa-
cinar cells (Figure 1) [34]. In addition to the above
mentioned compartments, a novel gland like mucinous
compartment known as the pancreatic ductal gland has
been identified to possess a characteristic molecular sig-
nature [35]. With different compartments present in the
pancreas, the question is from where do the pancreatic
progenitors arise?
Pancreas is an essential organ whose size is controlled
by the size of the progenitor population that is present in
the developing pancreatic bud [36]. On the other hand, the
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Figure 1. A comprehensive diagram de-
picting the evolution of cancer stem cells
from normal pancreas due to accumulation
of mutations, followed by its isolation and
characterization. (A) A simplistic represen-
tation of the adult pancreas. (B) A cross sec-
tion of the pancreas illustrates the important
components of the pancreas such as the acini,
ductal cells, centroacinar cells, islets of lan-
gerhans comprising the alpha, beta, delta,
gamma and epsilon cells. (C) Isolation of the
centro acinar cells using ALDH1 and Sca 1.
(D) The normal cells undergo mutation which
may give rise to cancer stem cells. (E) The net
result of mutation in either the stem cell,
progenitor cell or the differentiated cells leads
to the formation of cancer stem cells. (F)
Cancer stem cells are then isolated using
various methods such as the hoechst 33342
dye exclusion assay, surface marker based
isolation and the aldefluor assay. (G) The
isolated cancer stem cells are characterized
using various methods such as tumorsphere
assay, tumorigenicity assay, cell cycle analy-
sis, the ability to undergo asymmetric division
and the ability to withstand drug pressure.
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reduction in the number of progenitor cell population does
not control the size of the liver during developmental
stages [36]. Results showed the ability of pancreatic
progenitors to grow, divide and differentiate after a reduc-
tion in the Pdx1 progenitor pool inmice. However, it could
not increase the cell division rate in order tomake a normal
sized organ [36]. Progenitors isolated frommice are found
to bear several surface markers. For instance, Samuelson
et al. [37], showed that the highly proliferative pancreatic
progenitor population isolated from mice has been found
to express stem cells antigen 1- (Sca-1). Another study
showed the presence of Nestin positive multipotent pro-
genitor cells in the centrilobular ducts of the adult rat
pancreas [38]. Interestingly Smukler et al., demonstrated
the presence of insulin positive multipotent stem cells
which had the ability to divide, thereby contributing to
both pancreatic and neural lineages [39].
Recent reports propose that the biliary tree derived cells
are the precursors of pancreatic committed progenitors
[40]. There is evidence for the presence of pancreatic stem
cells and/or progenitors in the peribiliary gland (PBG)
which connects to the pancreatic duct glands within the
pancreas [40]. The stem cells in the peribiliary gland are
highly proliferative and they express pluripotencymarkers
such as NANOG, OCT4, and SALL4 but do not express
mature pancreatic markers [40].
Notably, Rovira et al. [41], demonstrated that ALDH1
expressing centroacinar cells behave like adult/stem pro-
genitor cells. Evidences for the origin of CSCs in pancreas
are very limited. A recent study demonstrated that the
centroacinar cells; which is located at the junction of acini
and ducts, has been suggested to be the origin of PanINs
and pancreatic ductal adenocarcinoma and since these
cells express stem cell markers it could be proposed that
CSCs could arise from the centroacinar cells [42]. Recent
evidence also demonstrated that DCLK1 expressing cells
in the Kras; p53; PdxCre mouse tumors show CSC like
phenotype which may have originated from centroacinar
cells [27]. Apart from the centroacinar cells, the differ-
entiated acinar cells could be an essential source of stem
cells as these cells are found to harbor facultative progen-
itor characteristics. Under favorable circumstances such
as organ injury these facultative progenitors attains a
precursor phenotype [43]. In the future, many studies are
required to prove the concept of CSCs origin from adult
pancreatic stem/progenitor cells.
PANCREATIC CSC NICHE
Stem cells survive in a niche which provides favorable
conditions for it to self-renew. Similarly, a tumor is
governed by its microenvironment/niche which encom-
passes several components such as the cancer associated
fibroblasts, CSCs, immune cells, signaling molecules,
blood vessels and the extracellular matrix. It has been
identified that tumor stroma is composed of pancreatic
stellate cells which undergoes the paracrineNodal/Activin
signaling thereby forming a paracrine niche for pancrea-
tic CSCs. It was reported that the pancreatic stellate
cells secrete the embryonic morphogens Nodal/Activin.
These secretions were found to support the in vitro
sphere formation and promote invasiveness of pan-
creatic CSCs [44]. Hamada et al. [45], has shown that
the presence of stellate cells improved the spheroid form-
ing ability of cancer cells and the expression of CSC
related genes such as Nestin, ABCG2 and LIN28 was
induced. Hence, the cross talk between the niche and the
CSCs remains pivotal.
DIFFERENT APPROACHES FOR ENRICHING
PANCREATIC CSCs
Due to the technical difficulties in isolating exclusively the
CSC population, several methods have been employed to
solely enrich the CSC population from the heterogeneous
cancer cells. The methods used are aldefluor assay,
Hoechst 33342 dye method and surface marker based
isolation (Figure 1).
Aldefluor assay
This assay has been developed based on the increased
aldehyde dehydrogenase (ALDH) activity in hematopoi-
etic stem cells. ALDH is required for the oxidation of
intracellular aldehydes thereby resulting in the oxidation
of retinol to retinoic acid [46]. The aldefluor assay
employs an ALDH fluorescent substrate called BOD-
IPY-aminoacetaldehye (BAAA). BAAA passively dif-
fuses into the living cells and gets converted into
BODIPY aminoacetate (BAA-) by the intracellular
ALDH. BAA- is retained inside the cells until it is effluxed
by ATP binding cassette (ABC) transporters [47]. To
determine the background fluorescence an ALDH inhib-
itor, Diethylaminobenzaldehyde (DEAB) is used. Using
this assay, Rasheed et al. [48], claimed that the ALDHC
cells have enhanced tumorigenic potential and they are
comparatively more invasive than the CD44CCD24C
pancreatic CSCs. Likewise Kim et al. [49], reported that
the ALDHhigh cells are highly tumorigenic compared to
the CD133C and ALDHlow cell population. Gemcitabine
treated xenograft tumors showed an enrichment of
ALDH1 positive cells suggesting that they can tolerate
chemotherapy similar to CSCs [50].
Hoechst 33342 dye exclusion assay
This method is one of the most commonmethods employ-
ed to isolate the side population (SP); based on its dye
efflux properties in various types of cancer cells. SP cells
constitute a subpopulation of cancer cells that can effi-
ciently efflux the fluorescent DNA binding dye, Hoechst
33342, by an ATP binding cassette (ABC) transporter.
This assay was initially employed to isolate SP cells from
rat C6 glioma cell line [51]. As the SP cells exhibit higher
tumorigenicity than non-SP cells it is believed that this
method is used to detect CSCs. As a control for sorting the
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CSCs, an ABC transporter inhibitor; such as verapamil or
reserpine, is used in order to determine the SP gate. These
DNA binding dyes inhibit the efflux of the Hoechst dye by
SP cells thus serving as an essential control. The main
limitation of using Hoechst dye is its toxicity to cells;
however, if the concentration and incubation time has been
standardized the level of toxicity could be minimized.
Small differences in cell densities, dye concentrations and
staining timings may affect the phenotype of the SP cells.
Despite these limitations, some researchers prefer to use
the SP method, or the marker independent method, as it
overcomes the barrier of using diverse CSC markers for
isolation. By using the hoechst 33342 dye exclusion assay
reports clearly show the presence of SP andNSP in various
cancers such as brain, lung, prostate and pancreatic
[26, 52–54].
POTENTIAL MARKERS USED FOR THE
ISOLATION OF PANCREATIC CSCs
Pancreatic CSCs can be isolated from cell lines or primary
tumors using the markers detailed below.
c-Met belongs to the receptor tyrosine kinase family
and is expressed in both normal and cancer cells [55]. The
ligand associatedwith this receptor is knownas hepatocyte
growth factor (HGF). It has been reported that pancreatic
cancer cells expressing high levels of c-Met (c-Methigh)
displayed increased self-renewal capacity and tumorigen-
ic potential as opposed to the non-expressing or c-Metlow
expressing cancer cells [28]. Inhibition of c-MET using
either small hairpin RNA or c-Met inhibitor resulted in
decreased tumor growth. Thiswork introduces c-Met as an
essential CSC marker in pancreatic cancer.
CD24 andCD44 are cell surface glycoproteins involved
in cell-cell interactions and cell adhesion. Epithelial spe-
cific antigen (ESA) which is also known as EpCAM is a
widely used marker for CSCs isolation in various cancers
[56]. Using these three markers, Li et al. [20], has dem-
onstrated the existence of pancreatic CSCs. They have
isolated the CD44C/CD24C/ESAC pancreatic CSCs from
the pancreatic tumors which accounted for 0.2–0.8% of
pancreatic cancer cells that displayed the CSC features
such as the self-renewal property and enhanced tumori-
genic potential as opposed to the marker-negative
population.
CD133 also known as Prominin1/AC133 is a surface
glycoprotein expressed in the progenitor cell populations
and it is a marker of CSCs of various cancer origins.
CD133 is found to be expressed in pancreatic CSCs as
demonstrated byHermann et al. [30]. They clearly showed
that CD133CCXCR4C CSCs were responsible for the
metastatic phenotype of the tumor and on depletion of
the CSCs carrying these signature markers; it resulted in
the abrogation of metastatic nature of pancreatic tumors
[30].
Apart from the aforementioned markers, ALDH1 is one
of the widely used markers to isolate pancreatic CSCs. In
addition, CXCR4Cwas used to denote a subset of CD133C
pancreatic CSCs which was associated with metastasis as
well as drug resistance. Recently, a novelmarker pancreatic
differentiation 2 (PD2) was identified to maintain the self-
renewal and drug resistance properties of pancreatic CSCs
[57].Oneof themost recent studies explored anovelmarker
integrinavb3 as aCSCdriver in lung, breast, and pancreatic
cancers which are highly resistant to erlotinib; a tyrosine
kinase inhibitor [58]. The Kras-RalB-NF-kB pathway and
the expression of the integrin were identified to be impor-
tant for the initiation of tumor, self-renewal, anchorage
independence and the resistance developed against erloti-
nib. Altogether, these markers could solely enrich the CSC
population from a heterogeneous cancer cell population
(Figure 2). Isolated CSCs are subsequently characterized
for its self-renewal and tumorigenic properties.
CHARACTERIZATION OF PANCREATIC CSCs
Once the CSCs are isolated using any of the previously
mentioned methods these cells are characterized using the
following assays:
In vitro tumorsphere assay
To demonstrate the self-renewal capacity and the tumor-
igenic potential of the CSCs an in vitro tumorsphere assay
is performed.Oneway to demonstrate the clonogenicity of
the CSCs or the SP fraction is by seeding them in few
numbers in a low attachment plate (with appropriate
replicates), which are further allowed to grow for approx-
imately 2 weeks. The total number of spheres formed is












Figure 2. A schematic representation of various pancreatic
cancer stem cell markers. Pancreatic CSC markers expressed on
the cell surface comprises markers such as CD133, CD44, CD24,
CXCR4, c-MET, ESA and DCLK1 and intracellular markers such
as ALDH1 and PD2. Multidrug transporters belonging to the ATP
binding cassette (ABC) superfamily expressed on the pancreatic
CSCs aids in effluxing the Hoechst 33342 dye during the CSC
isolation, thus mirroring the mechanism through which the chemo-
therapeutic drugs are being effluxed by the CSCs in pancreatic
cancer.
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serial dilution in order to demonstrate its self-renewal
property in the secondary generation. The true CSC
population will have the ability to form spheres faster
than the primary generation.
In vivo tumorigenic assay
In order to assess the tumorigenic potential of the CSCs,
these distinct cells are injected in NOD-SCID mice, nude
mice or NSGmice. In various cancers it has been reported
that any number between 1 to<1000 CSCs when injected
in mice have the ability to form a tumor [22, 59]. In
pancreatic cancer, it has been shown that 50% of the mice
developed tumor when 100 CD44CCD24CESAC cells
were injected in mice [20]. The primary tumors are
digested with collagenase and trypsin and CSCs isolated
from these tumors are injected into the secondary recipi-
ents [48]. These mice should have developed the tumors
even faster than that of the primary generation. Therefore,
these assays are essential to be carried out in order to prove
that the isolated CSCs are a true population (Figure 1).
MUCINS INCANCERSTEMCELLS/PANCREATIC
CANCER
Mucins are heavily glycosylated proteins which form a
protective barrier to the cell surface. They are character-
ized by a heavily O-glycosylated tandem repeat region,
rich in proline (P), threonine (T) and serine (S) residues
also known as the PTS domain. The slow transition from a
healthy to diseased state in pancreatic cancer is accom-
panied by an altered expression and localization ofmucins
[60]. There are asmany as 21members in themucin family
which are mainly divided into transmembrane and gel
forming proteins. So far, two of the transmembrane
mucins such as MUC1 and MUC4 have been found to
be associated with cancer stem cells [61, 62].
In pancreatic cancer, it has been demonstrated that the
down-regulation of MUC4 results in sensitizing the pan-
creatic cancer stem/progenitor cells to chemotherapeutic
drugs, thus serving as an important therapeutic means in
pancreatic cancer treatment [62]. Followed by this finding
it was identified that in ovarian cancer, MUC4 was over-
expressed in ovarian cancer cell line SKOV3, which led to
the increased expression of HER2. This in turn resulted in
increased CD133C population as well as side population
[63]. In the recent past, MUC1 was identified to be a
potentialmarker in pancreatic and breast cancer stemcells.
Engelmann et al. [64], has identified that around 77% of
breast CSCs isolated using the Hoechst 33342 dye method
were found to be MUC1bright cells. Similarly in pancreatic
cancer, Curry et al. [61], has identified that 80% of the
CSCs in patient samples expressed MUC1. Two sets of
CSCpopulationswere isolated frompancreatic cancer cell
lines such as BXPC3 and Panc-1 using the triple marker
such as CD44CCD24CEpCAMC and the CD133C cells.
CSCs isolated using the triple marker sorting were up to
46.7% and 19.8% in BXPC3 and Panc-1 cell lines respec-
tively. MUC1 expression was found to be detected at
higher levels in both the populations [61].
Mucins have gained significant importance in pancre-
atic cancer research. Therefore, it will be important to
explore mucins with respect to CSCs in the near future.
Apart from MUC1 and MUC4, other mucins such as
MUC5AC, MUC16 and MUC17 are yet to be explored
from the cancer stem cell viewpoint.
SIGNALING PATHWAYS INVOLVED IN THE
MAINTENANCE OF PANCREATIC CSCs
Since self-renewal is a common feature of normal stem
cells and CSCs, it is reasonable to believe that these cells
share the same signaling pathways. The following signal-
ing pathways such as Notch, Shh and Wnt play an impor-
tant role in the pancreatic CSCs.
In the normal pancreas, Notch signaling controls the
balance between the self-renewal and differentiation pro-
cesses [65]. Additionally, Notch signaling is important for
the pathogenesis of human cancers including pancreatic.
Studies showed that the overexpression ofNotch-1 resulted
in increased clonogenicity, migration, invasion and induc-
tion of EMT phenotype in Aspc-1; a pancreatic cancer cell
line. Moreover, the overexpression of Notch-1 resulted in a
significant increase in the pancreatosphere formationwhich
concomitantly expressed higher levels of the CSCmarkers,
EpCAM and CD44 [66]. Bao et al. [66], has identified that
Notch-1 signaling is crucial for the acquisition of EMT
phenotype. Likewise, Abel et al. [67], has identified that
Notch pathway is essential for the maintenance of pancre-
atic CSC population. They have observed that knockdown
of Hes1 using shRNA and inhibition of the Notch pathway
components by gamma secretase resulted in the reduction
of the self-renewal capacity of pancreatic CSCs. Altogeth-
er, these studies clearly suggest that Notch signaling is
important for the pancreatic CSC formation (Figure 3).
Hedgehog signaling pathway is essential for cell dif-
ferentiation and tissue patterning events during the embry-
onic development of the pancreas [68]. Among the three
hedgehog genes such as Sonic hedgehog (Shh), Indian
hedgehog (Ihh) and Desert hedgehog homolog (Dhh), Shh
shows the widest range of expression [68]. One of these
three ligands binds to the receptor Patched1, which
relieves the protein smoothened (Smo) from inhibition.
Smo triggers the activation of the downstream target genes
such as GLI family of transcription factors and PTCH
(Figure 3). It has been reported that a nine fold increase in
Shh mRNA levels has been found in the CD44C
CD24CESAC cells when compared to the unsorted pan-
creatic cancer cells [20]. Sonic hedgehog- Gli signaling is
identified to be essential for the pancreatic CSCs. Sulfor-
ane (SFN), an active component in cruciferous vegetables,
was found to inhibit the self-renewal capacity of pancre-
atic CSCs by blocking the hedgehog pathway [69].
In addition to the above mentioned pathways, there is
another pathway which is essential for the signaling in
6 A.P. Vaz et al.
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pancreatic CSCs. During embryonic development the
Wnt-b-catenin signaling pathway plays an important role
at different stages of pancreatic organogenesis. However,
inhibition of this pathway is necessary for pancreatic
specification during the early endoderm development
[70]. Canonical Wnt signaling is found to be important
for the progression of pancreatic cancer [71]. It has been
reported that in colorectal cancer Wnt signaling is asso-
ciated with EMT process and was found to activate a
transcription factor snail thereby facilitating EMT. Snail is
found to interact with b-catenin which is required for its
activation. Since EMT is a process present in CSCs these
findings suggest that b-catenin may have a role in pan-
creatic CSCs (Figure 3) [72]. However, in the future more
studies are required to prove the role of b-catenin in
pancreatic CSCs.
Apart from the three important signaling pathways
there are other pathways which are involved in the main-
tenance of pancreatic CSCs. A recent study has reported
that the inhibition of mTOR pathway by Rapamycin
resulted in decreased viability of CD133C pancreatic
cancer cells and reduced the sphere forming ability of
pancreatic cancer cells. These results suggest that the
mTOR pathway is essential for the self-renewal of pan-
creatic CSCs [73]. Another study claims that the NF-kB
pathway is highly activated in pancreatic CSCs. It was
shown that treatment with NF-kB pathway inhibitors
interrupts the stem cell-like properties [74]. Altogether,
several signaling pathways have been identified to play
significant roles in conserving the cancer stem cell phe-
notype in pancreatic cancer.
DRUG RESISTANCE AND EMT IN PANCREATIC
CSCs
The most important property of CSCs is to acquire the
EMT induced stemness phenotype which then leads to
GLI 
complex
WNT signaling Shh signaling Notch signaling
































Figure 3. Schematic representation ofWnt, Shh and Notch signaling cascades in normal stem cells and pancreatic cancer stem cells. A.
Wnt signaling pathway: Wnt proteins are secreted glycoproteins or ligands that transduces extracellular message to intracellular signaling
cascade by binding through frizzled receptors. In the absence of this ligand (off state),b-catenin is sequestered by a complex ofmolecules such as
Axin1, 2/APC/CK1a and GSK-3b, which is commonly known as destruction complex. Phosphorylation of b-catenin within this complex leads
to ubiquitin and proteosomal mediated degradation process. In the presence of WNT ligand (on state), WNT protein binds to frizzled receptors
along with its LRP5/6 co-receptor complex leading to activation of cytosolic phosphoprotein disheveled (DSH) resulting in interruption of the
destruction complex. The activated DSH will inhibit GSK-3b activity which in turn leads to cytosolic accumulation of b-catenin, subsequently
leading to nuclear translocation resulting in target genes activation. In normal stem cells, theWnt pathway signaling causes activation of its target
genes such asOCT4,Nanog and Sox-2 leading tomaintenance of self-renewal property [89]. In addition,Wnt pathway is inhibited byDickkopf 1
((DKK1), a soluble Wnt inhibitor) resulting in reduction of stem cell population [90]. B. Shh signaling pathway: Sonic hedgehog (Shh) is a
secreted and lipid modified ligand that binds to a transmembrane spanning receptor known as patched (Patch) leading to subsequent signal
transduction events. In the absence of Shh ligand, Patch will constitutively repress smoothened (smo), another transmembrane spanning protein,
having homology similar to G-protein coupled receptor (GPCR). Upon Shh ligand binding to Patch, smo inhibition by patch will be released,
which subsequently leads to activation of downstream GLI (GLI1, 2, 3) family of transcription factors. In pancreatic cancer cells, GLI
transcription factor activation leads to subsequent upregulation of Shh target genes such as FoxM1, Nanog, OCT4 and Sox2 [91–93]. These
markers play amajor role in the self-renewal nature of pancreatic cancer stemcells.C.Notch signalingpathway: In pancreatic cancer stemcells,
notch signaling cascade plays a vital role in stem cell maintenance and differentiation process. Notch receptor is composed of an extracellular
ligand binding domain, a single transmembrane spanning region and intracellular domain. Activation of notch signaling takes place through
binding of delta ligand with notch receptor between neighboring cells. Upon ligand binding to notch receptor, it will undergo a conformational
change that allows cleavage at extracellular portion of notch by a metalloprotease TNFa converting enzyme (TACE). Subsequently, the
intracellular portion of notch will also be cleaved by g-secretase, an intramembrane protease thereby releasing notch intracellular domain
containing portion (NICD). In pancreatic cancer cells, NICDwill translocate into the nucleus and interacts with its transcription factor RBP and
co activator p300 leading to activation of Epcam, CD44 and Hes1 genes [66, 67].
Pancreatic cancer stem cells 7
J Cancer Stem Cell Res  http://cancerstemcellsresearch.com
drug resistance to various chemotherapeutic agents. It has
beenwell evidenced that humanpancreatic cancer consists
of a subset of cells; known as the side population, which is
highly resistant to gemcitabine, a very commonly used
chemotherapeutic agent in pancreatic cancer therapy [75].
This minor subset of cells displayed an increased expres-
sion of genes associated with epithelial-mesenchymal
transition (SNAI2, LEF1), apoptotic regulation (FASLG,
ETS1) and multi-drug resistance (ABCG2 and ABCA9)
[75]. The cancer cells become resistant to drugs partly due
to the acquisition of EMT phenotype [17]. It has been
identified that the sensitivity of cancer cells is attributed by
the EMT process. The epithelial marker such as E-cad-
herin was found to be strongly expressed in the gemcita-
bine sensitive pancreatic cancer cells whereas the
gemcitabine resistant cells expressed mesenchymal mar-
kers such as vimentin and Zeb-1 [76]. Zeb1, a transcrip-
tional suppressor has been identified to be an important
player in the process of EMT. On silencing Zeb-1 in the
mesenchymal cell lines, the expression of the epithelial
markers such as E-cadherin, EVA1 and MAL2 was
increased andmost importantly the pancreatic cancer cells
gained sensitivity to chemotherapeutic drugs [77]. Anoth-
er report showed that pancreatic cancer cell lines; such as
AsPC-1, MIAPaCa-2, PANC-1, Hs766T and MPanc96
cells which were resistant to three different chemothera-
peutic drugs (gemcitabine, cisplatin and 5-fluorouracil),
displayed EMT phenotype [77]. The above mentioned
reports strongly suggest that drug resistance is associated
with EMT phenotype. The migrating cancer progenitor
cells play an important role in cancer progression and
metastasis [78]. Likewise, another study showed that the
gemcitabine resistant pancreatic cancer cells which
display EMT characteristics showed down-regulation
of single stranded small non coding RNAs namely micro
RNAs (miRNA) including miR-200b, miR-200c, let-7
(b-e) when compared to the gemcitabine sensitive pan-
creatic cancer cells. On re-expression of miR-200 in
gemcitabine resistant pancreatic cancer cells, EMT
markers such as ZEB1, vimentin and slug were down-
regulated [76]. This suggests that miRNAs are important
regulators in determining the EMT phenotype. Another
study showed that miRNAs such as miR99a, miR100,
miR-125b, miR-192 and miR-429 were differentially
expressed in pancreatic CSCs. These miRNA clusters
were found to be associated with the stem cell associated
mRNAs in pancreatic CSCs [79]. Overall, these studies
suggest that drug resistance and EMT are inter related
and they play an important role in the maintenance of
CSCs in pancreatic cancer.
STRATEGIES EMPLOYED TO TARGET
PANCREATIC CSCs
Pancreatic cancer remains to be one of the most challeng-
ing cancers due to its intrinsic and extrinsic drug resis-
tance, thereby leading to invasive carcinoma. Novel drugs
are being synthesized to combat this disease. CSCs are a
challenging factor for the chemotherapeutic treatments
including pancreatic cancer. Metformin is one of the most
significant drugs reported to have decreased the CSC
population as evidenced by the diminished expression of
CSCmarkers such as CD133, CD44, CXCR4 and SSEA-1
and self-renewal associated genes such as Nanog, Oct-4
and Sox2 [80].Metforminwas able to increase the reactive
oxygen species production in CSCs and reduce its mito-
chondrial transmembrane potential. The in vitro tumor-
sphere assay revealed a significant decrease in the size and
number of metformin treated spheres. Interestingly, they
have shown that metformin retarded the formation of
secondary and tertiary tumorspheres by hampering the
self-renewal capacity of these CSCs. In cancer cells, the
mode of action of this drug is by indirect activation of
AMP-activated protein kinase (AMPK) signaling fol-
lowed by inhibition of the mTOR activity thereby result-
ing in reduced cell proliferation and protein synthesis
whereas an AMPK/mTOR independent pathway occurs
in CSCs [80].
Another important drug named Salinomycin has been
extensively used in the field of CSCs. Salinomycin is
identified to target CD133C pancreatic CSCs. A combi-
natorial effect of Salinomycin and gemcitabine has been
used to eradicate pancreatic cancer in xenograft mice [81].
The combination of both drugs had an improved effect
against CSCs over the individual agents itself. This sug-
gests that administration of Salinomycin could therapeu-
tically improve the efficacy of gemcitabine for the
treatment of pancreatic cancer [81].
Sorafenib (SO), a multikinase inhibitor was used for
targeting pancreatic CSCs. Studies demonstrated that SO
administration led to the decreased spheroid formation,
clonogenicity, ALDH1 activity, proliferation, angiogen-
esis and induced apoptosis. On the other hand, it also led to
increased survival and regrowth of spheroid due to the SO
induced activation of NF-kB. Therefore, in addition to SO,
Sulforaphane (SF); a broccoli isothiocyanate, was also
used to efficiently target pancreatic CSCs. This combina-
torial treatment efficiently abolished SO-induced NF-kB
bindingwhich in turn led to abrogated spheroid formation,
ALDH1 activity, clonogenicity, induction of apoptosis
and tumor size reduction [82].
A novel drug namely cabozantinib (XL184) has been
identified to inhibit c-MET, a recently established pan-
creatic CSC marker. Cabozantinib, a FDA approved drug
decreased the viability and spheroid formation and also
induced apoptosis in cancer cells. It also inhibits self-
renewal property and the expression of CSC markers
including SOX2, c-Met and CD133. Strikingly, cabozan-
tinib increased the sensitivity of gemcitabine resistant
cells. When this drug was administered to 330 medullary
thyroid carcinoma patients, several side effects such as
diarrhea, weight loss, loss of appetite, oral pain, nausea,
hypertension, and hair color changes were reported.
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Regardless of these side-effects, this drug inhibited tumor
progression and led to reduced tumor size in some patients
[83].
Recent work by Zeng et al. [84], have demonstrated the
synergistic activities of MET/RON inhibitor BMS-
777607 and mTOR inhibitor AZD8055 on pancreatic
cancer and pancreatic CSCs. Together, these drugs target
the chemoresistant cancer cells and CSCs. Therefore,
novel drugs causing minimal side effects and maximal
targeting of CSCs is the current need in the field of
pancreatic CSCs. Moreover, there is a significant need in
the area of developing small molecular inhibitors and
nanoparticles targeted against CSCs to reduce the expres-
sion of the overexpressed proteins solely in CSCs. It is
extremely important to design and improve the combina-
torial therapies which could target the bulk of the tumor
cells, CSCs and the residual dormant cells. It is well
evident by now that CSC markers such as CD44, CD133
and CD24 are upregulated in pancreatic CSCs (Figure 2).
Thus, raising antibody against CSC surfacemarkerswould
be a major tool to target pancreatic CSCs. For example,
antibody raised against CD44 led to the inhibition of
pancreatic tumor initiation and postradiation recurrence
in mice [85].
Wang et al. [86], reported that successful targeting of
pancreatic CSCs could be achieved by targeting Notch
using natural agents such as genistein, curcumin, quercetin
and sulphorane. It has been identified that chloroquine
targets pancreatic CSCs by inhibiting CXCR4 and hedge-
hog signaling [87]. Thus, based on the above mentioned
reports it could be suggested that novel strategies encom-
passing combinatorial therapies could be used to achieve
improved treatment outcome for pancreatic cancer patients.
CONCLUSION AND PERSPECTIVES
The uncontrolled expansion of self-renewingCSCs results
in cancer. Extensive studies over the past several years
revealed the importance of this small subset of cells that
could sustain the tumor. Although there are several meth-
ods employed to isolate CSCs, there are limitations with
each of the currently used methods. Therefore, there is a
need to identify improvedmethods for isolating purely the
CSC population. Markers such as CD44, CD133 and ESA
have been well established in pancreatic cancer but they
serve as markers for other cancers as well. It is of utmost
importance to identify specific markers which aid in the
maintenance of pancreatic CSCs. As every organ has a
specific gene expression pattern, it would be ideal to
identify the specifics of pancreatic cancer. In the past, the
identification of circulating tumor cells opened a new
chapter in the field of cancer. The methods employed for
the detection of tumor cells circulating in the blood stream
are crucial. The most current methods used are based on
the surface marker expression such as EpCAM. Similarly,
if the CSCs have a sequence of signature markers
expressed on its surface specific for each type of cancer,
it enables the identification of CSCs, thereby facilitating
easy targeting of these cells.
Given that very few CSCs when injected in mice can
give rise to tumor much faster than the cancer cells,
successful targeting of CSCs with a combination of che-
motherapeutic agents could likely yield dramatic results.
Besides CSCs, the players of the tumor microenvironment
facilitate the pathogenesis of pancreatic cancer. As a
result, it can be suggested that tumor microenvironment
be considered as a crucial site for drug delivery. The most
effective way of targeting pancreatic cancer is by destroy-
ing the CSC niche or by altering the expression of the
important players which support the survival of CSCs. In
the future, in vivo animal studies which explore the
biology of pancreatic CSCs are required.
The signaling pathways such as Notch, Wnt and Shh
are altered in CSCs. Therefore, clinical trials should
focus on novel therapeutic agents that target CSCs and
the important molecules in the signaling pathways in
order to control the aggressiveness of pancreatic cancer.
Reversal of EMT phenotype will aid in the treatment of
pancreatic cancer. Different clonogenic CSCs have been
identified in many other cancers in the recent past. It is
also important to identify the clonogenicity of aggres-
sive CSCs in pancreatic cancer. Origin of CSCs is one
of the emerging fields; hence it is also important to
identify the specific origin of pancreatic CSCs in order
to target the CSCs.
The major problem with pancreatic cancer is tumor
recurrence. Once the drug is withdrawn or due to the
development of resistance towards drugs, the cancer
reappears. Therefore, there is a need to elucidate the
mechanisms of treatment resistance in patients. This could
be possible with the advancements in animal models
which are further administered with drugs; as the cure
for pancreatic cancer partly relies on the elimination of
pancreatic CSCs. Since, the genomic make up of each
individual is different; individualized or personalized
treatment is required to win the battle against cancer. In
vitro engineering of mesenchymal stem cells (derived
from pancreatic cancer patients) with anti-tumor genes
could yield in targeting the cancer cells [88]. Due to the
tumor homing capacity of the engineered mesenchymal
stem cells, this strategy holds promise towards pancreatic
cancer therapy. This strategy could be further expanded to
target cancer stem cells which may result in specific
treatment options for pancreatic cancer patients.
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